FITC/ PE - anti Human KAPPA/ CD19 - NaM76-5F3, A3-B1

Specificity: Anti- Kappa Light Chains reacts with free kappa chains as well as kappa chains in intact immunoglobulin molecules. The specificity has been ascertained as described below. Flow cytometry: When Anti- Kappa Light Chains is applied as described in the staining procedure in combination with Anti- CD19/ RPE, on lysed human whole blood, a specific staining of a part of the CD19- positive B lymphocytes is seen corresponding to the expected range of kappa light chain expression. Clinical applications: Flow cytometric analysis of single cell suspensions from formalin- fixed, paraffin- embedded tissue samples demonstrated that Anti- Kappa Light Chains labels reactive hyperplastic lymph nodes (10/ 10 cases). In non- Hodgkin’s lymphomas, the antibody labeled 4/ 10 cases. The remaining cases were positive for lambda light chains (5/ 10 cases) or showed no expression of light chains (1/ 10 cases). Flow cytometric analysis of peripheral blood lymphocytes demonstrated that Anti- Kappa Light Chains labels a proportion of B- cell chronic lymphocytic leukaemias. Thus, in one study of 121 cases , 37 were positive for kappa. In another study of 165 cases (3), 97 were positive for kappa. Anti- CD19, labels human B cells in peripheral blood, bone marrow and other tissues. Additionally, B- cell lymphoproliferative disorders gave positive reactions with the antibody, i. e. acute lymphoblastic leukaemia, chronic lymphocytic leukaemia, hairy cell leukaemia, lymphoblastic lymphoma (Burkitt type), centroblastic/ centrocytic lymphoma, and diffuse non- Hodgkin’s lymphoma. The antibody was shown to be unreactive with other cells in the human haema-topoietic system and did not react with non- haematopoietic cells, e. g. in kidney, liver, breast or lung tissues.

Please contact us at for specific academic pricing.